Australia's Dimerix rises on Denmark regulatory nod for clinical trial

Dimerix

01/02/2022 02:16

** Shares of Dimerix Ltd  DXB.AX  rise as much as 10.6% to
A$0.26, post their best intraday pct gain since Jan 4
    ** The drug developer says it received Danish Medicines
Agency's regulatory approval for its Phase 3 clinical trial for
DMX-200  urn:newsml:reuters.com:*:nASX9JtYHY
    ** Adds that trial will evaluate the efficacy and safety of
DMX-200 against a placebo in patients with FSGS kidney disease,
in which a scar tissue develops on parts of kidney that filter
waste from blood
    ** Stock hits highest level since Jan 24
    ** More than 820,000 shares change hands, compared with the
30-day average volume of about 550,000 shares 
    ** Stock down 4.1% this year, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))